LETTER TO THE EDITOR

A novel UBAP1 truncated variant in a Chinese family with hereditary spastic paraplegia

To the editor,

Hereditary spastic paraplegias (HSPs) are a group of neurodegenerative diseases predominately presented with weakness and spasticity in lower extremities. HSPs have high clinical and genetic heterogeneity and over 80 genes or loci have been linked to HSP over the past two decades (Mackay-Sim, 2021). Even so, appropriately 50% of affected individuals were still not genetically diagnosed. In 2019, two studies (Farazi Fard et al., 2019; Lin et al., 2019) identified pathological truncating variants within UBAP1 in autosomal dominant HSP pedigrees. These families are from Iran, USA, Germany, Canada, Bulgaria, Spain, and China, respectively, implying the diverse geographic origin for the UBAP1 variants. The phenotypes are predominantly pure early-onset HSP in these families (MIM # 618418). In this study, we reported a novel UBAP1 (NM_016525.5) truncating variant c.371dupT (p.Leu124Phefs*15) in a Chinese autosomal dominant HSP pedigree (Figure 1a). This study was approved by the Ethics Committee of Second Affiliated Hospital, Zhejiang University School of Medicine and written informed consents were obtained from the participants.

The proband is 33-year-old female with a history of progressive weakness and rigidity of lower limbs for 25 years. She had difficulty in climbing the stairs and walking stably. There is no muscle atrophy of lower extremities. Her mother had similar symptoms, while other familial members were unaffected. Physical examinations revealed normal muscle strength but increased muscle tension in lower extremities. Tendon reflex was brisk in four limbs and Babinski sign was positive bilaterally. Vibratory sensibility was lost in the distal end of lower limbs. Brain MRI revealed unremarkable information, except for several lacunar infarcts. Thoracic MRI displayed extensive atrophy. EMG revealed normal amplitude and conduction velocity of motor nerves and sensory nerves. We performed whole exome sequencing in the proband. After verifying by Sanger sequencing, we identified a heterozygous UBAP1 truncated variant c.371dupT (p.Leu124Phefs*15) (Figure 1b). We then performed Sanger sequencing in her available family members and found that her affected mother carried the same c.371dupT variant. This variant was absent in the ExAC, 1000G, gnomAD, and our in-house WES database that contain 500 Chinese controls. The affected residue was much conserved in different species (Figure 1c). According to the ACMG guideline (Richards et al., 2015), this variant should be assigned as pathogenic.

UBAP1, encodes the ubiquitin-associated protein 1 (UBAP1), a subunit of ESCRT-I complex. UBAP1 has two main domains, the UMA domain in the N-terminal region (17–63 aa) and a SOUBA domain in the C-terminal region. The former domain is associated with ESCRT-I complex, while the latter domain maintains ubiquitin homeostasis of early endosome processing. We constructed plasmids containing wild-type (WT) or mutant UBAP1 gene (NM_016525.5) and transfected the plasmids in HEK 293T cells. Western blot analysis revealed that this truncating variant actually led to the production of truncated mutant form of UBAP1, lacking the SOUBA domain (Figure 1d). We performed immunocytochemical staining for the EEA1 (early endosome marker) and Flag-fused UBAP1 in HeLa cells to elucidate the endosome function. The results showed the aberrant endosome aggregates (Figure 1e) and prominent enlarged endosome in cells over-expressing mutant UBAP1 (Figure 1f).

To date, 18 UBAP1 variants including the one identified here have been described (Bian et al., 2021; Bourinaris et al., 2020; Gu et al., 2020; Wang et al., 2020), and 17 of them occurred in Exon 4 of UBAP1 (Figure 1g), implying that Exon 4 is a potential hotspot region of UBAP1. In addition, all identified variants preserve the UMA domain but cause a loss of the SOUBA domain, implying that loss of ubiquitin binding would be detrimental. Further studies are required to elucidate the mechanism of SOUBA impairment causing HSP.

In summary, we identified a novel UBAP1 truncating variant in a Chinese autosomal dominant HSP pedigree.
Our findings expanded variant spectrum of UBAPI and further confirmed the pathogenicity of UBAPI variants in HSP.

ACKNOWLEDGMENTS
The authors would like to thank all the participants for their supports and willingness to participate in this study. Thanks for the technical support by the Core Facilities, Zhejiang University School of Medicine. This study was supported by the research foundation for distinguished scholar of Zhejiang University to Zhi-Ying Wu (188020-1938 10101/089) and the Fundamental Research Funds for the Central Universities.
Jiao Luo: data acquisition. Zhi-Ying Wu and Hong-Fu Li: data acquisition, interpretation of data. Wen-Wang: data acquisition, analysis, and interpretation of data, statistical analysis, drafting the manuscript. Pei-Shan Qiao Wei: data acquisition, analysis, and interpretation of data, funding, study design and conceptualization, data acquisition, analysis and interpretation of data, technical and material support, drafting, and critical revision of the manuscript.

CONFLICT OF INTEREST
The authors have declared no conflict of interest.

AUTHOR CONTRIBUTIONS
Qiao Wei: data acquisition, analysis, and interpretation of data, statistical analysis, drafting the manuscript. Pei-Shan Wang: data acquisition, analysis, and interpretation of data. Hai-Lin Dong: data acquisition, interpretation of data. Wen-Jiao Luo: data acquisition. Zhi-Ying Wu and Hong-Fu Li: funding, study design and conceptualization, data acquisition, analysis and interpretation of data, technical and material support, drafting, and critical revision of the manuscript.

ETHICAL STATEMENT
The study was approved by the Ethics Committees of Second Affiliated Hospital of Zhejiang University School of Medicine and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Specific national laws have been observed, too. Written informed consent was obtained for this study from all the patients prior to their inclusion in the study.

DATA AVAILABILITY STATEMENT
Data available on request from the authors.

REFERENCES
Bian, X., Cheng, G., Sun, X., Liu, H., Zhang, X., Han, Y., Li, B., & Li, N. (2021). Two novel truncating variants in UBAP1 are responsible for hereditary spastic paraplegia. *PLoS ONE*, 16(6), e0253871.

Bourinaris, T., Smedley, D., Cipriani, V., Sheikh, I., Athanasiou, Fragkouli, A., Chinnery, P., Morris, H., Real, R., Harrison, V., Reid, E., Wood, N., Genomics England Research, C., Vandrovcova, J., Houlden, H., & Tucci, A. (2020). Identification of UBAP1 mutations in juvenile hereditary spastic paraplegia in the 100,000 genomes project. *European Journal of Human Genetics*, 28(12), 1763–1768.

Farazi Fard, M. A., Rebelo, A. P., Buglo, E., Nemati, H., Dastsooz, H., Goker-Alpan, O., Cortese, A., Souyri, S., Abreu, L., Powell, E., Danzi, M. C., Martusseli, N. B., Bis-Brewer, D. M., Tao, F., Zarei, F., … Faghihi, M. A. (2019). Truncating mutations in UBAP1 cause hereditary spastic paraplegia. *American Journal of Human Genetics*, 104(6), 1251.

Faghihi, M. A. (2019). Truncating mutations in UBAP1 cause pure autosomal-dominant spastic paraplegia. *Brain*, 142(8), 2238–2252.

Bouilladoux, T., Ma, C., Pujol, A., Tan, Q. K., Schaaf, C. P., & Meng, L. (2020). Stop-gain mutations in UBAP1 on onset nonsyndromic hereditary spastic paraplegia. *Human Genetics*, 141(3), 363–373.

Gu, S., Chen, C. A., Rosenfeld, J. A., Cope, H., Launay, N., Flanagan, K. M., Waldrop, M. A., Schrader, R., Juusola, J., Goker-Alpan, O., Milunsky, A., Schluter, A., Troncoso, M., Pujol, A., Tan, Q. K., Schaaf, C. P., & Meng, L. (2020). Truncating variants in UBAP1 associated with childhood-onset nonsyndromic hereditary spastic paraplegia. *Human Mutation*, 41(3), 632–640.

Lin, X., Su, H. Z., Dong, E. L., Lin, X. H., Zhao, M., Yang, C., Wang, C., Wang, J., Chen, Y. J., Yu, H., Xu, J., Ma, L. X., Xiong, Z. Q., Wang, N., & Chen, W. J. (2019). Stop-gain mutations in UBAP1 cause pure autosomal-dominant spastic paraplegia. *Brain*, 142(8), 2238–2252.
Mackay-Sim, A. (2021). Hereditary spastic paraplegia: From genes, cells and networks to novel pathways for drug discovery. *Brain Sciences, 11*(3), 403.

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., Voelkerding, K., Rehm, H. L., & ACMG Laboratory Quality Assurance Committee. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine, 17*(5), 405–424.

Wang, J., Hou, Y., Qi, L., Zhai, S., Zheng, L., Han, L., Guo, Y., Zhang, B., Miao, P., Lou, Y., Xu, X., Wang, Y., Ren, Y., Cao, Z., & Feng, J. (2020). Autosomal dominant hereditary spastic paraplegia caused by mutation of *UBAP1*. *Neurogenetics, 21*(3), 169–177.